BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D.
Khan S, et al. Among authors: zajac kaye m.
J Hematol Oncol. 2022 Mar 9;15(1):23. doi: 10.1186/s13045-022-01241-3.
J Hematol Oncol. 2022.
PMID: 35260176
Free PMC article.